News 1+1丨Sinopharm's new vaccine, where is the new one?
As of today, four vaccines have been conditionally approved for marketing in China.
Two of them are from Sinopharm Sino Biotech, and the latest two approved are the adenovirus vector vaccine of Academician Chen Wei, and the other is the latest vaccine approved for marketing by Sinopharm.
Is this vaccine
different from before?
In addition to inactivated vaccines and adenovirus vector vaccines, will we have vaccines with new technical routes?
Sinopharm
already has a new crown vaccine,
Why do we have to produce another one?
Yang Xiaoming, Chairman of Sinopharm Group China Bio:
Sinopharm established the inactivated vaccine process at the beginning of its research and development last year, and also set up the two biological products research institutes of China Biotechnology Beijing and Wuhan to develop in parallel, in order to ensure that they can be developed and can be measured. We call
"double insurance" for
production and listing
.
Two New Coronary Inactivated Vaccines of Sinopharm Group
Is there a competitive relationship?
How should the vaccinators be selected?
Yang Xiaoming, Chairman of Sinopharm Group China Bio:
Judging from the current global demand for vaccines from the new crown epidemic, the supply is still less than the demand.
In terms of the production capacity of the two production lines deployed by Sinopharm China Biotech, we strive to produce more than 1 billion doses in 2021.
From this perspective, there is a balance between supply and demand, but for the global fight against the epidemic, vaccines are far from enough.
Yang Xiaoming, Chairman of Sinopharm Group China Bio:
From the perspective of process route, both vaccines are virus inactivated vaccines. From the clinical data obtained in the first, second, and third clinical phases, both of them have reached the national level. The requirements of the Supervisory Bureau.
1. Effectiveness.
According to the protection rate obtained from the three-phase clinical data, one reached 79.34% and the other reached 72.51%, both of which were better than the protection rate of more than 50% required by the World Health Organization.
2. Neutralizing antibody positive conversion rate.
Both vaccines are close to 100%, and can reach 100% in terms of critical illness protection rate.
Therefore, in terms of effectiveness and safety data, the choice of these two vaccines should be
equal
.
People who have been vaccinated against the new crown for more than half a year,
Do I need to get a third shot?
Yang Xiaoming, Chairman of Sinopharm Group China Bio:
According to the emergency use and marketing-approved immunization procedures, the interval between two injections is 21 to 28 days. The data after the two injections interval is valid for half a year. According to the observations so far, there is no need for half a year. Newly strengthen the argument of the third stitch.
Only after more detailed data comes out can we know whether to strengthen it and what the durability is. We look forward to more complete data from Phase III clinical trials for this data.
Inactivated vaccine of Sinopharm Group
Is
it effective against
mutated new coronavirus?
Yang Xiaoming, Chairman of Sinopharm Group China Bio:
Does the new crown vaccine have any effect on the mutant strain? The mutant strains in the UK and South Africa are now more representative, which poses a serious challenge to the effectiveness of the vaccine.
We used the second and third clinical sera, that is, the serum after immunization with the inactivated vaccine, to conduct cross-neutralization tests of domestic and foreign strains, including British and South African strains, and a dozen or so strains. The results show that we have These two mutant strains in South Africa are also neutralized, and nearly a dozen strains isolated in China are also effective in neutralizing, indicating that inactivated vaccine immunization is
effective against
the mutant strains encountered so far
.
People under 18
When can I get the new crown vaccine?
Yang Xiaoming, Chairman of Sinopharm Group China Bio:
People who are susceptible to the new crown virus are all age groups, and vaccine prevention is best for all age groups. However, when we are doing clinical phase one, two and three trials, we will do 18 to 18 for safety reasons. 59 years old, so the data for 18 to 59 years old comes out the earliest, followed by those over 60 years old, and the second is those under 17 years old and over 3 years old, which are divided into different ages.
Therefore, in emergency use, the approved age group is 18 to 59 years old.
For the Beijing Stock Exchange, which was listed on December 30 last year, and the Wuhan Stock Exchange, which was listed on February 25, the applicable age group in the listing specification is more than 18 years old, that is, over 18 years old, including all age groups over 60 years old.
For the 3 to 17-year-old age group, the clinical research data has been completed, and after finishing it, it must be submitted to the State Food and Drug Administration as soon as possible. The State Food and Drug Administration will approve the use of the 3-17 year old group according to regulations after reviewing in accordance with the regulations.